NCT05473520View on ClinicalTrials.gov

Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis

PHASE3RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

May 24, 2023

Primary Completion Date

January 31, 2030

Study Completion Date

January 31, 2030

Conditions
TuberculosisAcute Coronary SyndromePulmonary Hypertension (Diagnosis)
Interventions
DRUG

Doxycycline

A dose of 100 mg twice daily of doxycycline based on the recommended dose for adults which is commonly used for bacterial infections such as rickettsial infection, lyme disease and pelvic inflammatory disease.

DRUG

Placebo

Placebo + standard anti-tuberculous treatment

Trial Locations (6)

119228

RECRUITING

National University Hospital, Singapore

Unknown

NOT_YET_RECRUITING

Hospital Queen Elizabeth I, Kota Kinabalu

ACTIVE_NOT_RECRUITING

Klinik Kesihatan Luyang, Kota Kinabalu

RECRUITING

Klinik Kesihatan Menggatal, Kota Kinabalu

ACTIVE_NOT_RECRUITING

Universiti Malaysia Sabah (UMS), Borneo Medical and Health Research Centre, Kota Kinabalu

RECRUITING

TB Control Unit, Singapore

All Listed Sponsors
collaborator

Tan Tock Seng Hospital

OTHER

collaborator

Hospital Queen Elizabeth, Malaysia

OTHER_GOV

collaborator

National University of Singapore

OTHER

collaborator

University Malaysia Sabah

UNKNOWN

collaborator

Menggatal Health Clinic, Sabah, Malaysia

UNKNOWN

collaborator

Luyang Health Clinic, Sabah, Malaysia

UNKNOWN

lead

National University Hospital, Singapore

OTHER